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Abbreviations
and Acronyms
CAD = coronary artery
disease
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MI = myocardial infarction
OR = odds ratio
POCE = patient-oriented
composite endpoint
R-ZES = RESOLUTE
zotarolimus-eluting stent(s)
ST = stent thrombosis
TLF = target lesion failure
TLR = target lesion
revascularization
TV-MI = target vessel-
myocardial infarction
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1618New-generation drug-eluting stents
(DES) provide improved safety
and efﬁcacy compared with early-
generation DES and bare-metal
stents and represent the standard
of care in current clinical practice
(1). RESOLUTE zotarolimus-
eluting stents (R-ZES) and
everolimus-eluting stents (EES)
have been the ﬁrst new-generation
DES approved by the U.S.
Food and Drug Administration
and have been directly compared
in 2 large-scale randomized
trials showing similar outcomes
throughout 2 years of follow-up
(2,3). However, target
lesion revascularization (TLR)
continues to occur in >5% of
patients treated with new-
generation DES at 2 years,
suggesting that speciﬁc risk fac-
tors confer an increased riskof restenosis. Moreover, progression of coronary artery
disease (CAD) leading to revascularization of a segment not
previously treated results in rates of repeat revascularization
as high as 15% at 2 years. Identiﬁcation of clinical and
angiographic characteristics associated with restenosis and
progression of CAD in patients treated with new-generation
DES may help to address this clinical issue. We therefore
assessed 4-year clinical outcomes in the RESOLUTE
(A Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous Coro-
nary Intervention) All-Comers trial and identiﬁed predictors
of repeat revascularization in patients treated with new-
generation DES.
Methods
Full details on the RESOLUTE All-Comers randomized
clinical trial have been described elsewhere (4). The study
complied with the Declaration of Helsinki, all enrolled pa-
tients provided written informed consent, and ethics com-
mittees approved the protocol at all sites.
Study design. Overall, 2,292 patients with stable CAD or
acute coronary syndromes requiring revascularization were
randomized to the R-ZES (n ¼ 1,140) or the EES (n ¼
1,152). There were no restrictions in terms of the number ofreceived speaker fees from Abbott Vascular,
as received research grants and lecture fees from
and Medtronic. Dr. Windecker has received
Abbott Vascular, Biotronik, Boston Scientiﬁc,
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013; revised manuscript received November 29,treated lesions, vessels, implanted stents, or lesion length.
Follow-up was planned at 6 months, 1 year, and annually
thereafter through 4 years. Dual antiplatelet therapy (DAPT)
with daily aspirin (75 mg) and clopidogrel (75 mg) was
prescribed for at least 6 months. Low-dose aspirin was
continued indeﬁnitely. Study data were managed and
analyzed by an academic research organization (Cardialysis,
Rotterdam, the Netherlands).
Deﬁnitions and adjudication. The primary endpoint was
target lesion failure (TLF), deﬁned as the composite of
cardiac death, target vessel myocardial infarction (TV-MI),
or clinically-indicated TLR. Secondary endpoints were
the individual components of the primary endpoint, a
patient-oriented composite endpoint (POCE) (all-cause
death, any myocardial infarction [MI], any revasculariza-
tion), major adverse cardiac event (death, MI, emergent
bypass graft, or clinically-indicated TLR), target vessel
failure (cardiac death, TV-MI, or clinically-indicated target
vessel revascularization), their components, and stent
thrombosis (ST). The extended historical deﬁnition of MI
was used (5). TLR was deﬁned as any revascularization for a
stenosis within the stent or within a 5-mm border proximal
and distal to the stent. Any revascularization included all
TLR, all target vessel revascularization, and any non–target
vessel revascularization. ST was adjudicated according to the
Academic Research Consortium criteria (6). An independent
clinical events committee blinded to treatment allocation
adjudicated endpoints according to pre-speciﬁed deﬁnitions.
Statistical analysis. All analyses were conducted using the
intention-to-treat population. Comparisons between groups
were based on the Fisher exact test for categorical outcomes
and a 2-sample t test for continuous outcomes. The time-
sensitive nature of any response variable was analyzed us-
ing the Kaplan-Meier method. Baseline clinical, lesion,
procedure, and angiographic characteristics in the overall
trial population were analyzed for associations with TLR
and any revascularization throughout 4 years (univariate
analysis). A multiple logistic regression analysis was then
conducted with an entry criterion of 0.2 and a stay criterion
of 0.1 (multivariate analysis). Statistical analyses were con-
ducted using SAS software version 9.1 or later (SAS Insti-
tute, Cary, North Carolina).
Results
Follow-up data at 4 years were available for 1,122 (98.4%)
R-ZES patients and 1,124 (97.6%) EES patients (Online
Fig. 1). As previously reported, baseline clinical and angio-
graphic characteristics were well balanced (4) (Online
Table 1).
Clinical outcomes at 4 years. Clinical outcomes at 4-year
follow-up are shown in Table 1. TLF (15.2% vs. 14.6%,
p ¼ 0.68) and POCE (30.4% vs. 28.6%, p ¼ 0.36)
occurred with similar frequency in R-ZES– and EES-
treated patients. Figure 1 shows cumulative event rates
of TLF and POCE through 4 years for all patients. Rates
Table 1 Clinical Outcome at 4 Years
R-ZES
(n ¼ 1,122)
EES
(n ¼ 1,124) Difference (95% CI), % p Value
TLF 15.2 (171) 14.6 (164) 0.6 (2.3 to 3.6) 0.679
TVF 17.6 (198) 17.1 (192) 0.6 (2.6 to 3.7) 0.738
MACE 18.7 (210) 18.9 (212) 0.1 (3.4 to 3.1) 0.957
POCE 30.4 (341) 28.6 (321) 1.8 (1.9 to 5.6) 0.355
Death or TV-MI 12.9 (145) 13.1 (147) 0.2 (2.9 to 2.6) 0.950
Cardiac death or TV-MI 10.1 (113) 9.3 (105) 0.7 (1.7 to 3.2) 0.569
Death 8.5 (95) 8.6 (97) 0.2 (2.5 to 2.1) 0.940
Cardiac death 5.4 (61) 4.7 (53) 0.7 (1.1 to 2.5) 0.444
TV-MI 5.3 (60) 5.4 (61) 0.1 (1.9 to 1.8) 1.000
Q-wave 1.2 (13) 0.8 (9) 0.4 (0.5 to 1.2) 0.402
Non–Q-wave 4.4 (49) 4.6 (52) 0.3 (2.0 to 1.5) 0.839
Any revascularization 21.1 (237) 18.6 (209) 2.5 (0.8 to 5.8) 0.139
CABG 3.1 (35) 2.5 (28) 0.6 (0.7 to 2.0) 0.375
PCI 19.0 (213) 16.6 (187) 2.3 (0.8 to 5.5) 0.152
Any TLR 9.2 (103) 8.0 (90) 1.2 (1.1 to 3.5) 0.329
CABG 1.7 (19) 1.3 (15) 0.4 (0.7 to 1.4) 0.496
PCI 8.0 (90) 6.9 (78) 1.1 (1.1 to 3.3) 0.337
Any TVR 13.3 (149) 11.9 (134) 1.4 (1.4 to 4.1) 0.341
CABG 2.1 (24) 1.9 (21) 0.3 (0.9 to 1.4) 0.655
PCI 11.7 (131) 10.6 (119) 1.1 (1.5 to 3.7) 0.421
Clinically-driven TLR 7.0 (79) 6.5 (73) 0.5 (1.5 to 2.6) 0.615
CABG 1.2 (14) 1.2 (14) 0.0 (0.9 to 0.9) 1.000
PCI 6.2 (70) 5.5 (62) 0.7 (1.2 to 2.7) 0.474
Clinically-driven TVR 9.9 (111) 9.5 (107) 0.4 (2.1 to 2.8) 0.776
CABG 1.6 (18) 1.6 (18) 0.0 (1.0 to 1.0) 1.000
PCI 8.7 (98) 8.4 (94) 0.4 (1.9 to 2.7) 0.763
Deﬁnite or probable ST 2.3 (26) 1.6 (18) 0.7 (0.4 to 1.9) 0.228
Early (0–30 days) 1.1 (12) 0.5 (6) 0.5 (0.2 to 1.3) 0.165
Late (31–360 days) 0.6 (7) 0.2 (2) 0.4 (0.1 to 1.0) 0.108
Very late (361–1,440 days) 0.7 (8) 0.9 (10) 0.2 (0.9 to 0.6) 0.814
Deﬁnite ST 1.5 (17) 0.7 (8) 0.8 (0.1 to 1.7) 0.074
Early (0–30 days) 0.8 (9) 0.1 (1) 0.7 (0.2 to 1.3) 0.011
Late (31–360 days) 0.4 (5) 0.2 (2) 0.3 (0.2 to 0.7) 0.288
Very late (361–1,440 days) 0.4 (4) 0.4 (5) 0.1 (0.6 to 0.4) 1.000
Values are % (n).
CABG ¼ coronary artery bypass graft; CI ¼ conﬁdence interval; EES ¼ everolimus-eluting stent(s); MACE ¼ major adverse cardiac event(s);
PCI ¼ percutaneous coronary intervention; POCE ¼ patient-oriented cardiac event(s); R-ZES ¼ Resolute zotarolimus-eluting stent(s); ST ¼ stent throm-
bosis; TLF ¼ target lesion failure; TLR ¼ target lesion revascularization; TVF ¼ target vessel failure; TV-MI ¼ target vessel-myocardial infarction; TVR ¼
target vessel revascularization.
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1619of cardiac death (5.4% vs. 4.7%, p ¼ 0.44) and TV-MI
(5.3% vs. 5.4%, p ¼ 1.00) were comparable between
R-ZES– and EES-treated patients (Table 1). Repeat
revascularization occurred with similar frequency among
R-ZES– and EES-treated patients in terms of TLR
(9.2% vs. 8.0%, p ¼ 0.33) and any revascularization
(21.1% vs. 18.6%, p ¼ 0.14). Figure 2 shows cumulative
event rates of TLR and any revascularization through 4
years of follow-up for all patients. Rates of ST were similar
with the R-ZES and the EES at 4 years (deﬁnite or
probable: 2.3% vs. 1.6%, p ¼ 0.23; deﬁnite: 1.5% vs. 0.7%,
p ¼ 0.07) as well as very late ST (deﬁnite or probable:
0.7% vs. 0.9%, p ¼ 0.81; deﬁnite: 0.4% vs. 0.4%, p ¼
1.00) (Table 1). Cumulative event rates of deﬁnite or
probable ST through 4 years, overall as well as according
to a landmark analysis at 1 year, are presented in Figure 3.Of note, no differences were observed with respect to
DAPT adherence between the 2 groups through 4 years
of follow-up (Table 2).
Predictors of TLR. At 4 years, TLR occurred in 193
patients (8.6%). As summarized in Table 3 and Figure 4, the
following clinical and angiographic characteristics were
identiﬁed as independent predictors of TLR: younger age
(odds ratio [OR]: 0.98, 95% conﬁdence interval [CI]: 0.96
to 0.99, p ¼ 0.003), insulin-treated diabetes (OR: 1.97, 95%
CI: 1.25 to 3.11, p ¼ 0.004), higher SYNTAX (Synergy
between PCI with Taxus and Cardiac Surgery) score
(OR: 1.03, 95% CI: 1.02 to 1.05, p < 0.001), and treatment
of saphenous vein grafts (OR: 2.28, 95% CI: 1.12 to 4.68,
p ¼ 0.024), ostial lesions (OR: 2.17, 95% CI: 1.30 to 3.62,
p ¼ 0.003), or in-stent restenosis (OR: 2.44, 95% CI: 1.53
to 3.90, p < 0.001).
Figure 1 Cumulative Incidence of TLF and POCE
Target lesion failure (TLF) includes cardiac death, target vessel myocardial infarction, or clinically indicated target-lesion revascularization. Patient-oriented composite endpoint
(POCE) includes all-cause death, any myocardial infarction, or any revascularization.
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1620Predictors of any revascularization. At 4 years, any
revascularization occurred in 446 patients (19.9%). As
summarized in Table 3 and Figure 4, the following clinical
and angiographic characteristics were identiﬁed as inde-
pendent predictors of any revascularization: younger age
(OR: 0.98, 95% CI: 0.97 to 0.99, p ¼ 0.004), diabetes (OR:
1.38, 95% CI: 1.08 to 1.76, p ¼ 0.011), previous PCI
(OR: 1.64, 95% CI: 1.28 to 2.11, p < 0.001), ST-segment
elevation MI (OR: 0.73, 95% CI: 0.56 to 0.91, p ¼ 0.005),
smaller reference vessel diameter (OR: 0.76, 95% CI: 0.62 to
0.93, p ¼ 0.008), higher SYNTAX score (OR: 1.04, 95%
CI: 1.03 to 1.05, p < 0.001), and treatment of left anterior
descending (OR: 0.74, 95% CI: 0.58 to 0.94, p ¼ 0.013),
right coronary artery (OR: 1.30, 95% CI: 1.01 to 1.67,Figure 2 Cumulative Incidence of TLR and Any Revascularization
TLR ¼ target lesion revascularization.p ¼ 0.044), saphenous vein grafts (OR: 2.54, 95% CI: 1.38
to 4.68, p ¼ 0.003), ostial lesions (OR: 1.62, 95% CI: 1.06
to 2.48, p ¼ 0.026), or in-stent restenosis (OR: 1.60, 95%
CI: 1.10 to 2.32, p ¼ 0.014).
Discussion
The long-term 4-year clinical follow-up of this large-scale
contemporary all-comer trial can be summarized as fol-
lows: 1) the new-generation R-ZES and EES have a
similar safety and efﬁcacy proﬁle; 2) very late ST occurred
infrequently with no difference between the R-ZES
and the EES; 3) TLR represents less than one-half of
all repeat revascularization procedures; 4) independent
Figure 3 Cumulative Incidence of Deﬁnite or Probable Stent Thrombosis
Cumulative incidence of deﬁnite or probable stent thrombosis (ST) through 4 years overall (A) and according to a landmark analysis at 1 year (B). ARC ¼ Academic Research
Consortium.
Table 2 Adherence to DAPT
R-ZES
(n ¼ 1,140)
EES
(n ¼ 1,152) p Value
At 30 days
Aspirin 95.6 (1,082/1,132) 95.2 (1,083/1,138) 0.69
Clopidogrel 98.2 (1,112/1,132) 98.7 (1,123/1,138) 0.40
DAPT 93.9 (1,063/1132) 94.4 (1,074/1,138) 0.66
At 1 yr
Aspirin 95.0 (1,056/1,111) 94.2 (1,048/1,112) 0.45
Clopidogrel 87.9 (977/1,111) 87.1 (968/1,112) 0.56
DAPT 84.2 (935/1,111) 83.5 (928/1,112) 0.69
At 2 yrs
Aspirin 93.9 (1,023/1,089) 93.1 (1,013/1,088) 0.44
Clopidogrel 20.1 (219/1,089) 20.9 (227/1,088) 0.67
DAPT 18.1 (197/1,089) 18.2 (198/1,088) 0.96
At 3 yrs
Aspirin 92.5 (981/1,061) 92.3 (977/1,058) 0.94
Clopidogrel 15.1 (160/1,062) 16.2 (171/1,058) 0.51
DAPT 12.8 (136/1,061) 12.9 (136/1,058) 1.00
At 4 yrs
Aspirin 91.1 (931/1,022) 90.8 (931/1,025) 0.88
Clopidogrel 15.0 (153/1,022) 15.3 (157/1,025) 0.76
DAPT 12.1 (124/1,022) 11.8 (121/1,025) 0.84
Values are % (n/N).
DAPT ¼ dual antiplatelet therapy; other abbreviations as in Table 1.
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Table 3 Baseline Characteristics of Patients With and Without TLR or Any Revascularization at 4 Years
TLR Any Revascularization
Yes
(n ¼ 193)
No
(n ¼ 2,053) p Value
Yes
(n ¼ 446)
No
(n ¼ 1,800) p Value
Age, yrs 63.5  10.7 64.4  10.8 0.255 64.1  10.7 64.4  10.8 0.603
Male 73.6 (142/193) 77.0 (1,580/2,053) 0.288 76.9 (343/446) 76.6 (1,379/1,800) 0.895
BMI, kg/m2 28.1  4.9 (193) 27.8  4.3 (2,045) 0.275 28.2  4.9 (446) 27.7  4.2 (1,792) 0.048
Cardiac risk factors
Diabetes mellitus 33.2 (64/193) 22.6 (464/2,053) 0.001 30.7 (137/446) 21.7 (391/1,800) <0.001
Insulin treated 15.0 (29/193) 7.1 (145/2,053) <0.001 12.3 (55/446) 6.6 (119/1,800) <0.001
Hypertension 79.8 (154/193) 70.8 (1,454/2,053) 0.009 77.6 (346/446) 70.1 (1,262/1,800) 0.002
Hyperlipidemia 72.5 (140/193) 65.6 (1,346/2,053) 0.051 73.1 (326/446) 64.4 (1,160/1,800) <0.001
Current smoker 24.4 (47/193) 26.1 (536/2,053) 0.595 25.8 (115/446) 26.0 (468/1,800) 0.926
Previous MI 35.3 (66/187) 29.2 (587/2,010) 0.092 35.9 (156/434) 28.2 (497/1,763) 0.003
Previous PCI 47.7 (92/193) 30.3 (623/2,053) <0.001 46.2 (206/446) 28.3 (509/1,800) <0.001
Previous CABG 17.1 (33/193) 9.1 (187/2,053) <0.001 15.7 (70/446) 8.3 (150/1,800) <0.001
Clinical characteristics
Stable CAD 41.5 (80/193) 34.2 (702/2,053) 0.044 39.7 (177/446) 33.6 (605/1,800) 0.016
Unstable angina 19.2 (37/193) 19.2 (394/2,053) 0.995 19.5 (87/446) 19.1 (344/1,800) 0.849
AMI within 72 h 24.4 (47/193) 29.1 (597/2,053) 0.166 26.0 (116/446) 29.3 (528/1,800) 0.165
STEMI 33.3 (18/54) 48.4 (342/706) 0.689 37.7 (52/138) 49.5 (308/622) 0.025
NSTEMI 18.7 (36/193) 17.7 (364/2,053) 0.749 19.3 (86/446) 17.4 (314/1,800) 0.364
LVEF <30% 1.0 (1/101) 2.6 (29/1,098) 0.880 2.2 (5/232) 2.6 (25/967) 0.387
Target vessel
Left main 4.7 (9/193) 2.2 (45/2,053) 0.036 2.5 (11/446) 2.4 (43/1,800) 0.923
LAD 47.7 (92/193) 51.0 (1,047/2,053) 0.377 43.3 (193/446) 52.6 (946/1,800) <0.001
LCX 34.2 (66/193) 32.7 (671/2,053) 0.669 34.1 (152/446) 32.5 (585/1,800) 0.525
RCA 40.9 (79/193) 39.1 (802/2,053) 0.611 43.0 (192/446) 38.3 (689/1,800) 0.065
SVG 6.2 (12/193) 2.0% (41/2,053) <0.001 5.4 (24/446) 1.6 (29/1,800) <0.001
Arterial graft 0.5 (1/193) 0.1 (3/2,053) 0.272 0.4 (2/446) 0.1 (2/1,800) 0.163
Complexity of CAD
SYNTAX score 17.6  9.4 (156) 14.3  9.1 (1,834) <0.001 16.9  9.5 (367) 14.1  9.0 (1,623) <0.001
Type B2/C lesions 81.4 (341/419) 78.6 (3,189/4,057) 0.749 80.3 (730/909) 78.5 (2,800/3,567) 0.888
Lesions with thrombus 3.4 (13/381) 4.9 (183/3,729) 0.397 3.0 (25/834) 5.2 (171/3,276) 0.063
Ostial lesions 8.7 (36/412) 3.4 (138/4,016) <0.001 5.9 (53/899) 3.4 (121/3,529) <0.001
Total occlusion 13.9 (58/416) 13.7 (557/4,056) 0.958 13.6 (123/906) 13.8 (492/3,566) 0.606
Calciﬁed lesion 74.2 (299/403) 78.3 (3,098/3,958) 0.502 75.8 (666/879) 78.4 (2731/3,482) 0.434
Bifurcation lesion 31.4 (123/392) 29.6 (1,115/3,769) 0.330 29.5 (251/850) 29.8 (987/3,311) 0.891
In-stent restenotic lesion 20.7 (37/179) 7.0 (143/2,041) <0.001 15.0 (64/428) 6.5 (116/1,792) <0.001
TIMI ﬂow grade 0–2 20.7 (86/416) 23.2 (940/4,056) 0.668 20.6 (187/906) 23.5 (839/3,566) 0.236
Allocated DES
ZES 54.6 (238/436) 47.0 (1,936/4,118) 0.512 50.9 (474/932) 46.9 (1,700/3,622) 0.245
EES 42.9 (187/436) 52.0 (2,143/4,118) 0.713 46.9 (437/932) 52.3 (1,893/3,622) 0.281
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1623predictors of TLR and any revascularization are
overlapping and include clinical and angiographic
characteristics.
With regard to safety, R-ZES and EES are associated
with comparable risks of cardiac death, MI, and ST
through 4 years. Noteworthy, the rates of very late (1
year) ST were exceedingly low (0.4% with both devices).
These ﬁndings are in line with recent evidence indicating
that risks of ST no longer represent a limitation to the
use of DES (7–10).
We observed a substantial difference between patient- and
stent-related outcomes at 4 years. The former resulted in a
2-fold higher event rate, indicating that at least 50% of
adverse events occurring after DES implantation are not
related to the implanted device but rather to progression of
CAD at nontreated sites. Similar ﬁndings were observed in
terms of repeat revascularization procedures, among which
TLR events represent less than one-half of overall repeat
revascularization events. Therefore, optimization of sec-
ondary prevention and medical management appear as
important as the initial choice between the different types of
new-generation DES.
Predictors of TLR identiﬁed in this analysis are compar-
able to predictors identiﬁed in previous studies with early-
generation DES and bare-metal stents (11–15). Features of
angiographic complexity of CAD, including SYNTAX score,
were strong predictors of TLR. With respect to clinical
characteristics, age and diabetes continue to represent
signiﬁcant predictors of TLR (11,15). Overall, it is note-
worthy that patients treated with new-generation DES
feature the same predictors of TLR as patients treated
with early-generation DES. This indicates that efﬁcacy of
new-generationDES remains limited by the same clinical and
angiographic characteristics that affected early-generation
DES efﬁcacy.
Little evidence is available of the predictors of progression
of disease beyond the target lesion among patients treated
with coronary stent implantation. Our results are consistent
with those of the PROSPECT (Providing Regional Ob-
servations to Study Predictors of Events in the Coronary
Tree) study ﬁndings with respect to the impact of diabetes
and previous PCI on any revascularization (16). Moreover,
we identiﬁed absence of ST-segment elevation MI, target
lesion location, reference vessel diameter, and SYNTAX
score as additional predictors of disease progression.
Therefore, in addition to baseline clinical conditions,
angiographic complexity of CAD appears to play a promi-
nent role in disease progression. Although TLR represents
less than one-half of repeat revascularization procedures,
predictors of TLR and any revascularization are largely
overlapping. This suggests that restenosis and progression of
CAD at nontreated sites are inﬂuenced by similar clinical
and angiographic factors.
Study limitations. First, this is a post-hoc analysis of a
trial not primarily intended to investigate CAD progres-
sion. However, both TLR and any revascularization were
Figure 4 Independent Predictors of Target Lesion Revascularization and Any Revascularization
Independent predictors of target-lesion revascularization (top) and any revascularization (bottom). CI ¼ conﬁdence interval; ISR ¼ in-stent restenosis; LAD ¼ left descending
artery; OR ¼ odds ratio; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; STEMI ¼ ST-segment elevation myocardial
infarction; SVG ¼ saphenous vein graft; SYNTAX ¼ Synergy between PCI with Taxus and Cardiac Surgery.
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1624pre-speciﬁed secondary endpoints adjudicated by a blinded
clinical event committee. Second, the analysis of stent- and
patient-related outcomes was not pre-speciﬁed and needs to
be considered as hypothesis generating. Third, data on
compliance with medications, apart from DAPT, were not
available, and therefore it was not possible to evaluate
the impact of compliance on restenosis and progression
of CAD. Finally, we analyzed predictors in the overall
population irrespective of stent allocation. However, stent
type did not emerge as a predictor of TLR or of any
revascularization.Conclusions
At 4 years of follow-up, R-ZES and EES demonstrated
similar safety and efﬁcacy outcomes. TLR represented
less than one-half of all repeat revascularization procedures.
Patient- and lesion-related factors predicting the risk of
TLR and any revascularization were largely overlapping.
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